A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients
A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients(440 views) D'Alterio C, Avallone A, Tatangelo F, Delrio P, Pecori B, Cella L, Pelella A, D'Armiento FP, Carlomagno C, Bianco F, Silvestro L, Pacelli R, Napolitano M, Iaffaioli RV, Scala S
Int J Cancer (ISSN: 0020-7136), 2014 Jul 15; 135(2): 379-390.
Keywords: Cxcr4, Outcome, Predictive Model, Preoperative Radio Chemotherapy, Rectal Cancer, Capecitabine, Chemokine Receptor Cxcr4, Fluorouracil, Folinic Acid, Oxaliplatin, Raltitrexed, Stromal Cell Derived Factor 1, Adjuvant Chemoradiotherapy, Adult, Advanced Cancer, Area Under The Curve, Article, Cancer Prognosis, Cancer Recurrence, Cancer Resistance, Cancer Risk, Cancer Staging, Cancer Survival, Clinical Evaluation, Clinical Feature, Controlled Study, Female, High Risk Patient, Human, Human Tissue, Immunohistochemistry, Major Clinical Study, Multiple Cycle Treatment, Outcome Assessment, Preoperative Period, Priority Journal, Protein Expression, Protein Function, Rectum Cancer, Recurrence Free Survival, Recurrence Risk, Risk Assessment, Risk Factor, Area Under Curve, Chemokine Cxcl12, Disease-Free Survival, Drug Resistance, Neoplasm, Kaplan-Meier Estimate, Middle Aged, Neoadjuvant Therapy, Neoplasm Recurrence, Local, Neoplasm Staging, Proportional Hazards Models, Radiation Tolerance, Rectal Neoplasms, Roc Curve, Tumor Markers, Biological, Chemokine Cxcl12 Metabolism, Neoplasm Physiology, Local Metabolism Mortality Pathology, Cxcr Metabolism, Cxcr4 Metabolism, Rectal Neoplasms Metabolism Mortality Pathology, Biological Analysis,
Affiliations: *** IBB - CNR ***
Department of Oncological Immunology, Istituto Nazionale per Lo Studio e la Cura Dei Tumori Fondazione Giovanni Pascale, IRCCS-ITALIA, via M. Semmola, 80131 Naples, Italy
Department of Gastrointestinal Medical Oncology, Istituto Nazionale per Lo Studio e la Cura Dei Tumori Fondazione Giovanni Pascale, IRCCS-ITALIA, via M. Semmola, 80131 Naples, Italy
Department of Pathology, Istituto Nazionale per Lo Studio e la Cura Dei Tumori Fondazione Giovanni Pascale, IRCCS-ITALIA, via M. Semmola, 80131 Naples, Italy
Department of Surgical Oncology, Istituto Nazionale per Lo Studio e la Cura Dei Tumori Fondazione Giovanni Pascale, IRCCS-ITALIA, via M. Semmola, 80131 Naples, Italy
Department of Radiation Oncology, Istituto Nazionale per Lo Studio e la Cura Dei Tumori Fondazione Giovanni Pascale, IRCCS-ITALIA, via M. Semmola, 80131 Naples, Italy
Institute of Biostructures and Bioimages, National Council of Research (CNR), via T. de Amicis 95, 80145 Naples, Italy
Department of Biomorphological and Functional Science, Federico II University School of Medicine, via S. Pansini 5, 80131 Naples, Italy
Department of Molecular and Clinical Endocrinology and Oncology, Federico II University School of Medicine, via S. Pansini 5, 80131 Naples, Italy
Department of Diagnostic Imaging and Radiation Oncology, Federico II University School of Medicine, via S. Pansini 5, 80131 Naples, Italy
References: Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2012 (2012) CA Cancer J Clin, 62, pp. 10-2
Sauer, R., Becker, H., Hohenberger, W., Preoperative versus postoperative chemoradiotherapy for rectal cancer (2004) N Engl J Med, 351, pp. 1731-1740
Gunderson, L.L., Sargent, D.J., Tepper, J.E., Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: A pooled analysis (2004) J Clin Oncol, 22, pp. 1785-1796
Avallone, A., Delrio, P., Lastoria, S., Chemo-radiotherapy in locally advanced rectal cancer: What is the optimal strategy? (2008) Eur J Cancer Suppl, 6, pp. 70-73
Bujko, K., Glynne-Jones, R., Bujko, M., Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy?. A systematic review of randomised trials (2010) Ann Oncol, 21, pp. 1743-1750
Avallone, A., Aloj, L., Delrio, P., Multidisciplinary approach to rectal cancer: Are we ready for selective treatment strategies? (2013) Anticancer Agents Med Chem, 13, pp. 852-860
Rodel, C., Martus, P., Papadoupolos, T., Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer (2005) J Clin Oncol, 23, pp. 8688-8696
Bujko, K., Michalski, W., Kepka, L., Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: An analysis of outcomes in a randomized trial (2007) Int J Radiat Oncol Biol Phys, 67, pp. 369-377
Fietkau, R., Barten, M., Klautke, G., Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer (2006) Dis Colon Rectum, 49, pp. 1284-1292
Maas, M., Nelemans, P.J., Valentini, V., Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: A pooled analysis of individual patient data (2010) Lancet Oncol, 11, pp. 835-844
Valentini, V., Van Stiphout, R.G., Lammering, G., Nomograms for predicting local recurrence, #distant |metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials (2011) J Clin Oncol, 29, pp. 3163-3172
Kim, J., Mori, T., Chen, S.L., Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome (2006) Ann Surg, 244, pp. 113-120
Ottaiano, A., Franco, R., Talamanca, A., Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients (2006) Clin Cancer Res, 12, pp. 2795-2803
Zhang, S.S., Han, Z.P., Jing, Y.Y., CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients (2012) BMC Med, 10, p. 85
Saigusa, S., Toiyama, Y., Tanaka, K., Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy (2010) Ann Surg Oncol, 17, pp. 2051-2058
Orimo, A., Gupta, P.B., Sgroi, D.C., Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion (2005) Cell, 121, pp. 335-348
Ingold, B., Schulz, S., Budczies, J., The role of vascular CXCR4 expression in colorectal carcinoma (2009) Histopathology, 55, pp. 576-586
Brand, S., Dambacher, J., Beigel, F., CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation (2005) Exp Cell Res, 310, pp. 117-130
Thelen, M., Thelen, S., CXCR7, CXCR4 and CXCL12: An eccentric trio? (2008) J Neuroimmunol, 198, pp. 9-13
Miao, Z., Luker, K.E., Summers, B.C., CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature (2007) Proc Natl Acad Sci USA, 104, pp. 15735-15740
D'Alterio, C., Consales, C., Polimeno, M., Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer (2010) Curr Cancer Drug Targets, 10, pp. 772-781
Xu, H., Wu, Q., Dang, S., Alteration of CXCR7 expression mediated by TLR4 promotes tumor cell proliferation and migration in human colorectal carcinoma (2011) PLoS One, 6, pp. e27399
Avallone, A., Di Gennaro, E., Delrio, P., Neoadjuvant multidisciplinary phase II study (BRANCH) of an early bevacizumab schedule plus chemo-radiation therapy in rectal cancer: Efficacy, safety, and biomarkers (2012) AACR Meeting, , abstract LB219
Akishima-Fukasawa, Y., Nakanishi, Y., Ino, Y., Prognostic significance of CXCL12 expression in patients with colorectal carcinoma (2009) Am J Clin Pathol, 132, pp. 202-210
Pacelli, R., Conson, M., Cella, L., Radiation therapy following surgery for localized breast cancer:outcome prediction by classical prognostic factors and approximated genetic subtypes (2013) J Rad Res, 54, pp. 292-298
El Naqa, I., Bradley, J., Blanco, A.I., Multivariable modeling of radiotherapy outcomes, including dose-volume and clinical factors (2006) Int J Radiat Oncol Biol Phys, 64, pp. 1275-1286
Hernandez, L., Magalhaes, M.A., Coniglio, S.J., Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis (2011) Breast Cancer Res, 13, pp. R128
Carlomagno, C., Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: A phase II study (2009) Ann Oncol, 20, pp. 906-912
Drury, L.J., Ziarek, J.J., Gravel, S., Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways (2011) Proc Natl Acad Sci USA, 108, pp. 17655-17660
Heinrich, E.L., Lee, W., Lu, J., Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells (2012) J Transl Med, 10, p. 68
Hiller, D.J., Li, B.D., Chu, Q.D., CXCR4 as a predictive marker for locally advanced breast cancer post-neoadjuvant therapy (2011) J Surg Res, 166, pp. 14-18
Margolin, D.A., Silinsky, J., Grimes, C., Lymph node stromal cells enhance drug-resistant colon cancer cell tumor formation through SDF-1α/CXCR4 paracrine signaling (2011) Neoplasia, 13, pp. 874-886
Allegra, C.J., Yothers, G., O'Connell, M.J., Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: Results of NSABP protocol C-08 (2011) J Clin Oncol, 29, pp. 11-16
Dewdney, A., Cunningham, D., Tabernero, J., Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C) (2012) J Clin Oncol, 30, pp. 1620-1627
Willett, C.G., Duda, D.G., Ancukiewicz, M., A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer (2010) Oncologist, 15, pp. 845-851
Hiratsuka, S., Duda, D.G., Huang, Y., C-X-C receptor type4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells (2011) Proc Natl Acad Sci USA., 108, pp. 302-307
Xu, L., Duda, D.G., Di Tomaso, E., Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer (2009) Cancer Res, 69, pp. 7905-7910
De Clercq, E., The AMD3100 story: The path to the discovery of a stem cell mobilizer (Mozobil) (2009) Biochem Pharmacol, 77, pp. 1655-1664
Gunderson, L. L., Sargent, D. J., Tepper, J. E., Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: A pooled analysis (2004) J Clin Oncol, 22, pp. 1785-1796
Zhang, S. S., Han, Z. P., Jing, Y. Y., CD133 (+) CXCR4 (+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients (2012) BMC Med, 10, p. 85
Drury, L. J., Ziarek, J. J., Gravel, S., Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways (2011) Proc Natl Acad Sci USA, 108, pp. 17655-17660
Heinrich, E. L., Lee, W., Lu, J., Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells (2012) J Transl Med, 10, p. 68
Hiller, D. J., Li, B. D., Chu, Q. D., CXCR4 as a predictive marker for locally advanced breast cancer post-neoadjuvant therapy (2011) J Surg Res, 166, pp. 14-18
Margolin, D. A., Silinsky, J., Grimes, C., Lymph node stromal cells enhance drug-resistant colon cancer cell tumor formation through SDF-1 /CXCR4 paracrine signaling (2011) Neoplasia, 13, pp. 874-886
Allegra, C. J., Yothers, G., O'Connell, M. J., Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: Results of NSABP protocol C-08 (2011) J Clin Oncol, 29, pp. 11-16
Willett, C. G., Duda, D. G., Ancukiewicz, M., A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer (2010) Oncologist, 15, pp. 845-851
Xu, L., Duda, D. G., Di Tomaso, E., Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer (2009) Cancer Res, 69, pp. 7905-7910
A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients
A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients
No results.
A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients